NKCx Histopathological outcome* within 12 months after cervix cytology in 2021 |
231 Jönköping |
Benign | LSIL | HSIL | AIS | Cancer | Other | PAD missing | Total | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cytologi | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel |
Benign sample | 101 | 1.2% | 25 | 0.3% | 8 | 0.1% | . | . | . | . | . | . | 8398 | 98.4% | 8532 | 100.0% |
ASCUS | 275 | 28.0% | 270 | 27.5% | 112 | 11.4% | 2 | 0.2% | . | . | 5 | 0.5% | 317 | 32.3% | 981 | 100.0% |
LSIL | 62 | 20.7% | 120 | 40.1% | 57 | 19.1% | 1 | 0.3% | . | . | . | . | 59 | 19.7% | 299 | 100.0% |
Atypical glandular cells/AGC | 1 | 12.5% | 1 | 12.5% | 1 | 12.5% | 3 | 37.5% | 1 | 12.5% | . | . | 1 | 12.5% | 8 | 100.0% |
ASC-H | 9 | 13.0% | 16 | 23.2% | 43 | 62.3% | 1 | 1.4% | . | . | . | . | . | . | 69 | 100.0% |
HSIL | 2 | 2.4% | 13 | 15.3% | 67 | 78.8% | . | . | 1 | 1.2% | 1 | 1.2% | 1 | 1.2% | 85 | 100.0% |
Squamous cell cancer | . | . | . | . | 1 | 100.0% | . | . | . | . | . | . | . | . | 1 | 100.0% |
Totalt | 450 | 4.5% | 445 | 4.5% | 289 | 2.9% | 7 | 0.1% | 2 | 0.0% | 6 | 0.1% | 8776 | 88.0% | 9975 | 100.0% |
NOTE: Histopathological outcome from T83x taken into account. |
This list includes only one diagnosis (the highest ranking) per person, applies to both Cyt and Pad. |
* Harmonization of PAD codes classification between analysis registry and process registry has been carried out. PAD Class 0 (non diagnostic, unreasonable diagnosis) is excluded, and next PAD counts instead. |
The classes 2a, b, c and 3a (suspected premalignant, pre-malignant UNS, HPV, suspected malignant) are grouped into 'Other'. |
Process Registry's Class 1 (benign), 2d (LSIL) and 3b (manifest cancer) have all been introduced without exception. Some codes that occur beyond the scope of the process registry has been added to the different categories. |
Snomed codes in the category Cancer: |
---|
M80703, M81403 |